New Product: Retsevmo (selpercatinib) 80 mg capsules

Selpercatinib monotherapy is licensed for advanced RET fusion-+ve non-small cell lung cancer and advanced RET fusion-+ve thyroid cancer in adults following prior treatments, and advanced RET-mutant medullary thyroid cancer in patients from 12 years age following prior treatments.

electronic Medicines compendium